Last reviewed · How we verify
Dichloroacetate
At a glance
| Generic name | Dichloroacetate |
|---|---|
| Also known as | sodium dichloroacetate, DCA, Leucine, Tyrosine |
| Sponsor | University of Nottingham |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) (PHASE2)
- Regulation of Brain Glucose Metabolism in Type 1 Diabetes (EARLY_PHASE1)
- Expanded Access Treatment Protocol With DCA for Patients With PDCD
- Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency: (PHASE3)
- A Clinical Trial to Evaluate Dichloroacetate (DCA) as a Treatment for Endometriosis-associated Pain (NA)
- Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers (PHASE1)
- Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes (EARLY_PHASE1)
- Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dichloroacetate CI brief — competitive landscape report
- Dichloroacetate updates RSS · CI watch RSS
- University of Nottingham portfolio CI